Schrödinger Q1 2026 slides: AI platform advances amid transition

Schrödinger reported Q1 2026 revenue of $58.6 million, above consensus by 21.78%, but EPS missed at a $0.81 loss versus a $0.64 loss expected and revenue declined 1.6% year over year. Drug discovery revenue surged 124% to $22.9 million while software revenue fell 21% amid the hosted licensing transition, with management reiterating 2026 ACV guidance of $218 million to $228 million and 2028 targets for positive adjusted EBITDA. The company also highlighted the upcoming Bunsen AI co-scientist launch and continued monetization of its therapeutics portfolio, though shares slipped 0.31% after hours to $12.80.

Analysis

SDGR is at an inflection where the market is still valuing it like a slow-growth software vendor, while management is trying to re-rate it as a platform plus monetizable pipeline. The key second-order effect is that the hosted transition temporarily depresses recognized revenue and gross margin, but it also shifts the mix toward higher-retention, usage-linked economics that should make the recurring base more durable once the revenue catch-up completes. That means the near-term multiple compression is likely more about accounting drag than demand destruction, but the market will need evidence that ACV growth keeps compounding while the hosted mix scales.

Bunsen is the real catalyst because it changes the product from a static discovery toolkit into an embedded workflow layer. If the agentic layer meaningfully increases DPMTA throughput, the value capture could migrate from seats to utilization, which is a much larger pool but also raises execution risk: customers may pilot it quickly, yet budget reclassification and procurement friction can delay monetization by several quarters. The most important watch item is whether throughput-based pricing expands ARPU faster than legacy software revenue decays; if not, the transition can look like growth but still underwhelm on operating leverage.

The therapeutics portfolio provides a hidden valuation floor and a convexity kicker, but the market is likely still discounting it as optionality rather than an asset with repeatable realization. The clustering of partner M&A wins is positive for sentiment, yet it also raises expectations that every good readout or partner decision will be treated as a near-term monetization event, which can create disappointment if the cadence slows. The cleaner contrarian setup is that SDGR is less a single-product story and more a sum-of-parts with multiple shots on goal; that argues for patience, but only if cash burn remains contained and software ACV doesn’t decelerate for two consecutive quarters.

Key Decisions for Investors

• Long SDGR on weakness for a 6-12 month horizon; use the post-earnings drift near the 52-week low as entry, with upside driven by Bunsen launch and hosted-transition visibility. Risk/reward is attractive if ACV stays 10-15% growth and the market stops capitalizing temporary margin compression as permanent.
• Pair long SDGR / short a basket of slower-growth software names with similar small-cap duration but no pipeline optionality. The thesis is that SDGR’s downside is supported by cash plus therapeutics assets, while upside is levered to a product-cycle reset over the next 2-4 quarters.
• Buy SDGR Jan-2027 call spreads to express the 2028 EBITDA path without paying full equity downside. This fits a catalyst chain of Bunsen adoption, hosted revenue conversion, and margin recovery, with better convexity than outright stock.
• If SDGR rallies on Bunsen headlines without a corresponding ACV inflection, fade the move tactically. The market may front-run usage monetization before procurement and billing actually convert into revenue, creating a 1-2 quarter timing mismatch.